Laura DeForge
Principal Scientist, Biochemical and Cellular Pharmacology
"I find it very rewarding to be involved in identifying new therapeutic proteins, particularly given Genentech's proven success in bringing novel therapeutics to patients."
-
My Keywords
Assay Technology, Automation Technology, Immunology -
My Department
Biochemical and Cellular Pharmacology
I joined Genentech in September of 1994. I was focused primarily on the anti-IL-8 project at the time and found it very exciting to be collaborating with scientists whose work I had admired while I was a postdoc working on IL-8 biology.
Years later, I still find that the combination of fast-paced, quality work and collaboration with world-class scientists creates a very challenging and gratifying work environment.
My Focus
In my group, as in much of AAT as a whole, we develop assays needed to help move Research projects forward into development.
We use many approaches, including traditional ELISAs, various solution phase binding technologies, enzymatic assays, and many types of cell-based assays, including cell binding, proliferation, and primary leukocyte response assays. We also evaluate and implement new technologies, including approaches to multiplexed protein analysis. The primary focus of my group is currently on immunology-related projects.
Publications & Recognition
- Species-dependent serum interference in a sandwich ELISA for Apo2L/TRAIL
- J Immunol Methods 2007 Mar 30; 320(1-2): 58-69
- DeForge LE, Shih DH, Kennedy D, Totpal K, Chuntharapai A, Bennett GL, Drummond JH, Siguenza P, Wong WL
- View Abstract on PubMed
- Structure of C3b in complex with CRIg gives insights into regulation of complement activation
- Nature 2006 Nov 9; 444(7116): 217-20
- Wiesmann C, Katschke KJ, Yin J, Helmy KY, Steffek M, Fairbrother WJ, McCallum SA, Embuscado L, DeForge L, Hass PE, van Lookeren Campagne M
- View Abstract on PubMed
- Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells
- Blood 2006 Nov 1; 108(9): 3103-11
- Lee CV, Hymowitz SG, Wallweber HJ, Gordon NC, Billeci KL, Tsai SP, Compaan DM, Yin J, Gong Q, Kelley RF, DeForge LE, Martin F, Starovasnik MA, Fuh G
- View Abstract on PubMed
- University of Michigan, Department of Pathology
- Postdoctoral Fellow
- 1989-1993
- University of Michigan, Department of Pharmacology
- Ph.D
- 1984-1989
- University of Michigan, Cellular and Molecular Biology
- B.S.
- 1980-1984
Publications & Recognition
- Species-dependent serum interference in a sandwich ELISA for Apo2L/TRAIL
- J Immunol Methods 2007 Mar 30; 320(1-2): 58-69
- DeForge LE, Shih DH, Kennedy D, Totpal K, Chuntharapai A, Bennett GL, Drummond JH, Siguenza P, Wong WL
- View Abstract on PubMed
- Structure of C3b in complex with CRIg gives insights into regulation of complement activation
- Nature 2006 Nov 9; 444(7116): 217-20
- Wiesmann C, Katschke KJ, Yin J, Helmy KY, Steffek M, Fairbrother WJ, McCallum SA, Embuscado L, DeForge L, Hass PE, van Lookeren Campagne M
- View Abstract on PubMed
- Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells
- Blood 2006 Nov 1; 108(9): 3103-11
- Lee CV, Hymowitz SG, Wallweber HJ, Gordon NC, Billeci KL, Tsai SP, Compaan DM, Yin J, Gong Q, Kelley RF, DeForge LE, Martin F, Starovasnik MA, Fuh G
- View Abstract on PubMed
- Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling
- J Biol Chem 2005 Jan 21; 280(3): 2205-12
- Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A
- View Abstract on PubMed
- Substrate capacity considerations in developing kinase assays
- Assay Drug Dev Technol 2004 Apr; 2(2): 131-40
- DeForge LE, Cochran AG, Yeh SH, Robinson BS, Billeci KL, Wong WL
- View Abstract on PubMed
- Modeling oncogene addiction using RNA interference
- Proc Natl Acad Sci USA 2008 Aug 26; 105(34): 12480-4
- Miller K, Meng G, Liu J, Hurst A, Hsei V, Wong WL, Ekert R, Lawrence D, Sherwood S, DeForge L, Gaudreault J, Keller G, Sliwkowski M, Ashkenazi A, Presta L
- View Abstract on PubMed
- Design, construction, and in vitro analyses of multivalent antibodies
- J Immunol 2003 May 1; 170(9): 4854-61
- Miller K, Meng G, Liu J, Hurst A, Hsei V, Wong WL, Ekert R, Lawrence D, Sherwood S, DeForge L, Gaudreault J, Keller G, Sliwkowski M, Ashkenazi A, Presta L
- View Abstract on PubMed
- Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation
- Cytokine 2001 Nov 7; 16(3): 106-19
- Leong SR, DeForge L, Presta L, Gonzalez T, Fan A, Reichert M, Chuntharapai A, Kim KJ, Tumas DB, Lee WP, Gribling P, Snedecor B, Chen H, Hsei V, Schoenhoff M, Hale V, Deveney J, Koumenis I, Shahrokh Z, McKay P, Galan W, Wagner B, Narindray D, Hebert C, Zapata G
- View Abstract on PubMed
- Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety
- J Pharmacol Exp Ther 2001 Oct; 299(1): 31-8
- Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA
- View Abstract on PubMed
- Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
- Nat Med 2001 Apr; 7(4): 383-5
- Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A
- View Abstract on PubMed
- Effect of IFN-gamma on the killing of S. aureus in human whole blood. Assessment of bacterial viability by CFU determination and by a new method using alamarBlue
- J Immunol Methods 2000 Nov 1; 245(1-2): 79-89
- DeForge LE, Billeci KL, Kramer SM
- View Abstract on PubMed
- A neutralizing monoclonal antibody specific for the dimer interface region of IL-8
- Cytokine 2000 Nov; 12(11): 1620-9
- Deforge LE, Lowman HB, Leong SR, Chuntharapai A, Jin Kim K, Hebert CA
- View Abstract on PubMed
- Safety and antitumor activity of recombinant soluble Apo2 ligand
- J Clin Invest 1999 Jul; 104(2): 155-62
- Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH
- View Abstract on PubMed
- Biological assays for C-X-C chemokines
- Methods Enzymol 1997; 287: 69-88
- Baly D, Gibson U, Allison D, DeForge L
- View Abstract on PubMed
- Regulation of interleukin 8 gene expression by oxidant stress
- J Biol Chem 1993 Dec 5; 268(34): 25568-76
- DeForge LE, Preston AM, Takeuchi E, Kenney J, Boxer LA, Remick DG
- View Abstract on PubMed
- Oxygen radical scavengers selectively inhibit interleukin 8 production in human whole blood
- J Clin Invest 1992 Nov; 90(5): 2123-9
- DeForge LE, Fantone JC, Kenney JS, Remick DG
- View Abstract on PubMed
